to Within two days of the second piece of good news from the active ingredient developer Biontech from Mainz, Germany: According to data to be one of the candidates of the company for a Corona vaccine, the share of Biontech rises on the stock exchange on Wednesday afternoon, at times by more than one-tenth; however, the note in the course of.
just yesterday, the company had reported a cash injection of state Investor Temasek from Singapore. With the price jump, investors rewarded the news, the Healthy administered BNT162b1-called vaccine candidate have proven to be well tolerated and a dose-dependent immune response is triggered.
BNT162b1 is one of four vaccine candidates of Biontech. In the previous research phase, it has been 45 adults in America are administered. Nine of them were given a Placebo.
In the case of two groups of subjects receiving two different doses of the drug, had been found to be neutralizing antibodies. The amount was in one case almost Double, and in the other case, nearly three times higher than in patients with defeated Corona infection.
"A strong get immune response"
Biontech had in April in this country in the race to approval for clinical Tests on a possible Corona vaccine. The company is cooperating with the American pharmaceutical company Pfizer. Biontech-in-chief Ugur Sahin will show quoted by the Reuters news Agency, with the words: "These initial study results that the vaccine has an immune activity, and a strong immune response triggers."
In the next phase of the research, more than 30,000 healthy volunteers could be involved, such as Biontech tells more. And: Should extend the study successfully, and the vaccine will receive regulatory approval, plan to the two companies until the end of 2020, up to 100 million doses of the Vaccine and to be able to until the end of 2021 may be more than 1.2 billion doses of Vaccine to produce.“Updated Date: 02 July 2020, 16:19